抗原特异性体外扩增VIII因子调节性T细胞诱导血友病A小鼠免疫耐受
该研究在血友病A小鼠中建立了一种临床可行的方案:从FVIII致敏小鼠中分选CD25高表达调节性T细胞,经FVIII、抗原呈递细胞和IL-2特异性扩增,再通过抗CD3/抗CD28微珠等进一步扩增10至20倍。扩增后的FVIII特异性Treg在体外抑制活性更强,过继转移可显著抑制抗FVIII免疫应答并维持长期耐受。
要点
- FVIII特异性扩增的Treg比非特异性扩增和初始Treg抑制活性更强。
- 过继转移FVIII特异性Treg可显著抑制血友病A小鼠抗FVIII免疫应答。
- 二次FVIII质粒攻击后,FVIII特异性免疫耐受仍得以维持。
核心结论
- FVIII特异性致敏和扩增方案可获得更强效的Treg,抑制抗FVIII抗体应答并诱导长期耐受。
研究设计与样本
- 从FVIII致敏小鼠中分离Treg,按CD25高表达分选,用FVIII、抗原呈递细胞和IL-2特异性扩增。
- 随后用抗CD3/抗CD28微珠、抗Crry抗体和IL-2进一步培养,实现10至20倍扩增。
- 对扩增Treg进行表征,并在体外和体内测试其抑制活性。
主要发现
- 体外FVIII特异性抑制实验显示,FVIII特异性扩增Treg比非特异性扩增和初始Treg抑制活性更强。
- 过继转移至血友病A小鼠后,FVIII特异性扩增Treg在抑制FVIII质粒处理小鼠的抗FVIII免疫应答方面显著更强效。
- 二次FVIII质粒攻击后,FVIII特异性免疫耐受仍得以维持。
临床怎么用
- 该方案为过继Treg细胞疗法调节抗FVIII免疫应答提供了临床可行的思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following protein replacement therapy, one-third of severe hemophilia A patients develop antibodies to factor VIII (FVIII), which also hinders the efficacy of gene therapy. Regulatory T cells (Tregs) have a naturally suppressive function that potentially reduces the immune response to FVIII therapy. Furthermore, antigen-specific Tregs are functionally much more potent than polyclonal cells. Adoptive transfer of antigen-specific Tregs can effectively suppress anti-FVIII antibody responses. OBJECTIVE: Develop a clinically feasible protocol to enrich and expand Tregs specific to FVIII for suppressing anti-FVIII immune responses. METHODS: Regulatory T cells are isolated from FVIII-sensitized mice, sorted on CD25high markers, and expanded specifically with FVIII, antigen-presenting cells, and interleukin 2 (IL 2). Subsequently, Tregs are further cultured with anti-CD3/anti-CD28 beads, anti-Crry antibodies, and IL 2 to achieve 10-fold to 20-fold expansion. Expanded Tregs are characterized and tested for their suppressive activity in vitro and in vivo. RESULTS: In vitro FVIII-specific suppressive assays indicate that FVIII specifically expanded Tregs are more suppressive than non-specifically expanded and naive Tregs. Adoptive transfer of expanded Tregs into HemA mice showed that FVIII-specifically expanded Tregs are significantly more potent in suppressing anti-FVIII immune responses in FVIII plasmid-treated HemA mice. Moreover, the FVIII-specific immune tolerance is maintained after a secondary challenge with FVIII plasmid. CONCLUSIONS: Our results demonstrate that the FVIII-specific sensitization and expansion protocol yields more potent Tregs to suppress anti-FVIII antibody responses and induce long-term tolerance to FVIII, increasing the potential for adoptive Treg cell therapy to modulate anti-FVIII immune responses.
引用
- Smith BM, Lyle MJ, Chen AC, et al. Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice. J Thromb Haemost. 2019. PMID: 31609041. doi:10.1111/jth.14659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。